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Abstract
Cellular senescence is a major hurdle for primary cell-based tissue engineering and regenerative medicine. Telomere
erosion, oxidative stress, the expression of oncogenes and the loss of tumor suppressor genes all may account for
the cellular senescence process with the involvement of various signaling pathways. To establish immortalized cell
lines for research and clinical use, strategies have been applied including internal genomic or external matrix microenvironment modification. Considering the potential risks of malignant transformation and tumorigenesis of genetic
manipulation, environmental modification methods, especially the decellularized cell-deposited extracellular matrix
(dECM)-based preconditioning strategy, appear to be promising for tissue engineering-aimed cell immortalization.
Due to few review articles focusing on this topic, this review provides a summary of cell senescence and immortalization and discusses advantages and limitations of tissue engineering and regeneration with the use of immortalized
cells as well as a potential rejuvenation strategy through combination with the dECM approach.
Keywords: Cell senescence, Decellularized cell-deposited extracellular matrix, Differentiation, Immortalization,
Proliferation, SV40, Tissue engineering
Background
Tissue and organ failure is a prominent health issue that
cannot be ignored. Surgical intervention, organ transplantation, artificial substitutes and mechanical devices
are methods to address this issue but all have undesirable short- and long-term consequences [1]. Tissue engineering is an attractive method that enables fabrication
of functional tissue for tissue regeneration as well as the
establishment of physiological and pathological models for mechanistic studies [2]. This technique can harness the intrinsic regenerative potential of primary cells
and expand them in a controlled environment before
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reintroduction into the patient’s body. These natural,
synthetic or semisynthetic tissue and organ mimics are
expected to function normally in a tissue-specific pattern as required [1, 3]. However, primary cells derived
from non-cancerous tissues have a finite lifespan and
decreased proliferation ability when cultured in vitro.
After a limited number of divisions, cells enter a viable
state of permanent quiescence, termed cellular senescence [4]. Cellular senescence, regulated by both intrinsic
and extrinsic factors, is characterized as two key phenotypes, a stable proliferation arrest and altered secretory
pathway, the senescence-associated secretory phenotype
(SASP) [5].
In order to acquire an abundant number of cells for
functional tissue engineering, cellular senescence is
the major obstacle that needs to be overcome. Numerous attempts have been made in past decades to deal
with cellular senescence in order to achieve successful immortalization of primary cells. To establish
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immortalized cell lines for research and clinical use,
strategies have been applied including internal genomic
or external matrix microenvironment modification.
Considering the potential risks of malignant transformation and tumorigenesis of genetic manipulation, environmental modification methods, especially
the decellularized cell-deposited extracellular matrix
(dECM)-based preconditioning strategy, appear to be
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promising for tissue engineering-aimed cell immortalization. Due to few review articles focusing on this
topic, this review provides a summary of cell senescence and immortalization and discusses advantages
and limitations of tissue engineering and regeneration
with the use of immortalized cells as well as a potential
rejuvenation strategy when combined with the dECM
approach (Fig. 1).

Fig. 1 A schematic diagram of immortalization strategy combined with the decellularized cell-deposited extracellular matrix approach to
overcome cell senescence and promote tissue regeneration
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Cellular senescence
Cellular senescence is a process that imposes irreversible proliferative arrest on cells in response to internal
and external environmental changes. Various stressors, including progressive telomere erosion, oxidative stress, the expression of oncogenes and the loss of
tumor suppressors, contribute to the occurrence of cellular senescence.
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Premature senescence

Senescence also happens in conditions that are not
dependent on telomere erosion or dysfunction. This process is often referred to as “premature” since it can arrest
growth prior to reaching the “Hayflick limit” [23]. Various conditions have been identified that may result in
premature cellular senescence.
Stress‑induced senescence

Replicative senescence

As vital structures that cap and protect the ends of linear chromosomes [6], shortening of telomeres happens
at every fission which eventually causes cells to reach
their “Hayflick limit” which halts growth after approximately 60 population doublings [4, 7]. When telomeres are too short to function normally for capping,
replicative senescence (M1 stage, a cellular growth
arrest) occurs [8–10]. The critically short telomeres
are detected by cells as double-strand breaks and trigger a deoxyribonucleic acid (DNA) damage response
(DDR) that consists of a series of signaling events centered on two anti-proliferative mechanisms, the p53/
p21 and p16/tumor suppressor retinoblastoma protein
(Rb) pathways. This cessation allows cells to repair the
DNA damage, but if the damage continues to exceed a
certain limit, apoptosis or senescence may occur [11].
Regulated by its upstream partner p16, one of the cyclin-dependent kinase inhibitors (CKIs), Rb controls cell
cycle progression from G1 into S phase by binding to
and suppressing the activity of E2F transcription factor
1 (E2F1) [10, 12, 13].
Many researchers have verified the importance of both
pathways in directing senescence as the suppression of
either p53 or Rb alone failed to achieve cell immortalization [14–17]. However, there were still reports showing
that, in human mammary epithelial cells and mesenchymal stem cells (MSCs), inactivation of p16 alone allows
human cells to avoid senescence [18, 19]. Meanwhile, in
human diploid fibroblasts, the p53 mutant alone is able
to suppress cellular senescence [20]. These findings raise
the possibility that these two pathways may function differently among different cell strains.
However, abrogation of the p53/p21 and p16/Rb pathways will only lead to a “pre-immortal” state instead of an
“immortal” status for cells. Terminal telomere shortening
still exists and will eventually lead to the M2 stage, characterized as massive cell death [10, 15, 21]. In most cases,
the stabilization of telomeres is achieved through the
introduction of telomerase, an enzyme that synthesizes
telomeric repeats and adds them to the ends of chromosomes for the compensation of inevitable loss with each
round of DNA replication [22].

During a long-term in vitro cell expansion, laboratory
culture conditions, generally defined as a lack of surrounding cell types and support from extracellular matrix
(ECM), abnormal growth factors and oxygen (O2) level,
expose the cell to excessive oxidative stress and induce
oxidant production [24–27]. The excessive levels of reactive oxygen species (ROS), including hydrogen peroxide
(H2O2), hydroxyl radical 
(OH−) and superoxide anion
−
(O2 ), are detectable during long-term culturing of
MSCs, accounting for stress-induced senescence [24–
26]. H2O2 could directly affect cellular DNA, trigger DDR
and subsequent p16/Rb and p53 pathways, leading to cell
cycle arrest [28–32].
Oncogene‑induced senescence

There is accumulating evidence showing both in vitro
[33–35] and in vivo [36, 37] oncogene activation, including Ras, Raf, BRAF (human gene that encodes a protein
called B-Raf ) and E2F1, can cause an irreversible cell
growth arrest, termed oncogene-induced senescence. In
normal primary cells, Ras activation leads to compulsory
replication, triggering DDR and the subsequent senescence-based pathways [33, 38, 39]. Raf encodes proteins
that function as a downstream effector of the Ras family and activate the extracellular signal-regulated kinase
(MAPK) kinase (MEK) in cascade, which in turn, activates extracellular signal regulated kinase 1/2 (ERK1/2)
[40]. Interestingly, Raf itself is able to elicit senescence
in IMR-90 cells [34]. The p16/Rb and p53 pathways are
crucial mediators of oncogene-induced senescence; however, the p16/Rb pathway in oncogene-induced senescence acts differently than in replicative senescence [33,
41, 42]. The BRAF gene, a downstream effector of Ras, is
an intracellular effector of the MAPK signaling cascade
that facilitates transmembrane signal transduction [43].
In primary cells, the expression of BRAFV600E is known
to induce transient stimulation of proliferation and subsequently trigger cellular senescence as demonstrated
in normal cells including melanocytes [44], fibroblasts
[45] and stem cells [46]. E2F1 is the founding member of
the E2F family, a regulatory protein that drives cell cycle
progression through interaction with Rb [47]. When a
cell prepares to enter the S phase of the cell cycle, E2F1
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is released from the Rb-E2F1 complex, activating the
downstream target genes regulating normal entry into
S phase [48]. Interestingly, in normal human fibroblasts,
E2F1 and its target gene p14 (ARF) are responsible for
the induction of cellular senescence [35]. Meanwhile,
E2F1 knock-out mouse embryonic fibroblasts demonstrated attenuated senescence and ROS levels [49].
Tumor suppressor loss‑induced senescence

Tumor suppressors are the counterpart of oncogenes, and
their loss can elicit cellular senescence. Depletion of NF1
(Neurofibromatosis 1), a tumor suppressor gene, induces
senescence in human fibroblasts [50]. Similarly, loss of
BTG3 (B-cell translocation gene 3), a member of the antiproliferative BTG gene family and a downstream target of
p53, triggers cellular senescence as well [51]. Inactivation
of VHL (von Hippel-Lindau tumor suppressor) induces
an efficient senescence in mouse fibroblasts and primary
renal epithelial cells under atmospheric conditions (21%
O2); however, loss of VHL only causes a decreased cell
proliferation instead of cell arrest in human renal epithelial cells [52, 53]. Similarly, acute loss of tumor suppressor
gene PTEN (phosphatase and tensin homolog) induces
growth arrest through the p53-dependent cellular senescence pathway in mouse prostate both in vitro and in vivo
whereas, in systemic lupus erythematosus patients, the
complete loss is significantly related to advanced cancer
and poor outcomes [54–56]. These findings raise the possibility that tumor suppressors may function differently
according to different species and cell types.

Signaling pathways involved in cellular senescence
Despite the abovementioned p53/p21 and p16/Rb pathways, other signaling pathways are also involved in
cellular senescence, including, but not limited to, transforming growth factor β (TGFβ)/bone morphogenetic
protein (BMP), Wingless/Int (Wnt)/β-catenin, MAPK,
phosphatidylinostitide 3 kinase (PI3K)/protein kinase B
(AKT)/mammalian target of rapamycin (mTOR), Hippo,
NOTCH, fibroblast growth factor (FGF) and insulin-like
growth factor (IGF) and hypoxia inducible factor (HIF)
(Fig. 2).
TGFβ/BMP signaling pathways

TGFβ is a classic regulator for chondrogenic differentiation but its role in cell expansion remains controversial
[57, 58]. TGFβ activation is positively involved in the
induction of cellular senescence of all kinds of species
[59–61]. In human breast cancer cells, TGFβ negatively
mediates telomerase activity through its downstream
effector, Smad3 [62, 63]. For stress-induced senescence,
TGFβ contributes to ROS production and activation of
DDR during the senescence of human fibroblasts and
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bone marrow-derived MSCs (BMSCs) [64, 65]. The
kinase ataxia-telangiectasia mutated (ATM) is a key
player in nuclear DDR [66]. Meanwhile, TGFβ is required
for oncogene-induced senescence that is independent
of the p16/Rb and p53 pathways; attenuation of TGFβ
inhibits premature senescence in human mammary epithelial cells [67, 68].
BMPs are secreted signal factors belonging to the TGFβ
superfamily and are involved in embryonic development
and cellular processes [69]. Similar to the function of
TGFβ, BMP receptor II/Smad3 contributes to telomerase
inhibition and telomere shortening in human breast cancer cells, leading to replicative senescence [70]. Similar
results were observed in primary cells as the BMP signaling axis plays an important role in oncogene-induced
senescence of mouse fibroblasts [71].
Wnt/β‑catenin pathway

Wnts are highly conservative proteins that participate
in embryonic development and homeostatic mechanisms in adult tissues [72]. Wnt signals appear to be an
important regulator of both premature senescence and
replicative senescence. On one hand, the Wnt/β-catenin
signaling pathway interacts with the p53/p21 pathway
for ROS production to induce MSC senescence [73–76].
On the other hand, Wnt3a/β-catenin also plays a critical
role in hedging replicative senescence of MSCs, probably
through regulation of a telomerase subunit—telomerase
reverse transcriptase (TERT) [72, 77]. Meanwhile, Wnt/
β-catenin signaling enhances rat nucleus pulposus cell
senescence as well as induces the expression of TGFβ,
another strong promoter of cellular senescence [78].
MAPK pathway

The MAPK signaling cascade, mainly including ERK,
c-Jun N-terminal kinase (JNK) and p38, regulates several physiological and pathological processes [40]. p38
is well-recognized to be involved in premature cellular
senescence [79, 80]. The major role of the p38 pathway
in oncogene-induced senescence is induced by the oncogene Ras or its downstream effector, Raf-1 [81, 82]. Ras
provokes premature senescence through activation of
the MEK/ERK pathway, followed by p38 activation [81].
Shin and colleagues found that ERK2 is responsible for
Ras-induced senescence in mouse embryonic fibroblasts [83]. Despite premature senescence, ERK is also
actively involved in replicative senescence and suppression of ERK signaling rescues cardiac progenitor cells
from replicative senescence when expanded in vitro [84].
The JNK signal was reported to be active in responding to a wide range of DNA-damaging agents from both
endogenous and exogenous causes and JNK phosphorylation is involved in senescence-associated matrix
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Fig. 2 Signaling pathways mediating the cellular senescence process. In response to telomere erosion, ROS production, the expression of
oncogenes and the loss of tumor suppressors, various signaling pathways including TGFβ, BMP, Wnt, MAPK, FGF, IGF, HIF and Hippo pathways are all
actively involved in cell cycle regulation, which eventually influences the cellular senescence process of primary cells

metalloproteinase-1 production in response to ROS in
IMPR-90 cells [85–89]. However, the senescence-promoting role of JNK was challenged as it was also revealed
to antagonize p38-induced p16 activation [90]. Moreover,
JNK acts as a negative regulator of p53 tumor suppressor
to suppress p53-dependent senescence in mouse embryonic fibroblasts [91]. An increase of intracellular ROS
levels can suppress the growth of cancer cells and induce
cellular apoptosis by mediating MAPK signaling components [92].
PI3K/AKT/mTOR pathways

PI3Ks and their downstream mediators AKT and mTOR
constitute the core component of the PI3K/AKT/mTOR
signaling pathway which is precisely controlled under

normal physiological conditions and is a frequently
hyperactivated pathway in cancer [93]. Similar to the
MEK-ERK pathway, PI3K is one of the main downstream
effectors of Ras dependent signaling and its activation
plays dual roles in cell cycle regulation as it can promote
cell cycle progression as well as cause cell cycle arrest
[94]. Recent studies reveal the involvement of PI3K/
AKT/mTOR in the regulation of replicative senescence
in human vascular smooth muscle cells [95]. Moreover,
a constitutively active, myristoylated form of AKT leads
to oncogene-induced senescence in primary cultured
human endothelial cells and murine fibroblasts; the loss
of PTEN triggers senescence through activation of the
PI3K/AKT pathway in mouse prostate [56, 96]. However,
a recent report subverted the positive role of the PI3K/
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AKT/mTOR pathway in senescence-induction by introducing the fact that activation of this pathway abolished
BRAFV600E-induced senescence in both primary human
fibroblasts and primary human melanocytes [97]. Moreover, targets of the PI3K/AKT signaling pathway have been
found to promote cell survival [98] and the activation of
the PI3K/AKT pathway can be induced by TGFβ, leading to a pro-survival/anti-apoptotic effect in both human
nasopharyngeal carcinoma cells [99] and mesenchymal
cells/fibroblasts [100].
Hippo pathway

The Hippo pathway is a tumor suppressor pathway; dysregulation of this pathway can lead to uncontrolled cell
proliferation and tumorigenesis [101]. Yes-associated
protein 1 (YAP), a major downstream effector of the
Hippo pathway, is phosphorylated and inactivated by
the serine/threonine kinases large tumor suppressor 1
(LATS1) and LATS2 [102, 103]. YAP dephosphorylation
is associated with the senescence of rat nucleus pulposus cells and overexpression of YAP in primary human
keratinocytes blocks clonal evolution and induces cell
immortalization [104, 105]. Coordination of the Hippo
pathway and p53 occurs in response to various types of
stress signals including replication and oncogenic Ras.
LATS2 cooperates with p53 to induce p21 expression,
resulting in cellular senescence [106]. LATS2 also plays
an important role in the oncogenic H-Ras induced stress
checkpoint in a p53-dependent pathway [107].
Notch pathway

The Notch pathway is an evolutionarily highly conserved
signaling pathway that is associated with a variety of cellular processes including cell-fate determination, proliferation and death. In mammals, the Notch family has five
ligands and four receptors [108, 109]. There is accumulating evidence that abnormal Notch signaling has been
implicated in multiple facets of cancer biology, and Notch
can behave as either an oncogene or a tumor suppressor depending on cell context [110, 111]. The oncogenic
function of Notch has been demonstrated in several
types of cancer including melanoma [112], breast cancer
[113] and brain tumors [114]. Activated Notch 1 significantly enhances the rate of glycolysis, which prevents cellular senescence of human adipose-derived stromal cells
(ADSCs) through HIF1 activation and p53 inactivation
[115]. On the other hand, the Notch pathway is found to
serve as a tumor suppressor in the progression of carcinoma including bladder cancer [116], medullary thyroid
carcinoma [117] and pancreatic cancer [118]. Enforced
Notch activation in human endothelial cells is associated with cellular senescence with the involvement of p16
[119]. Down-regulation of Notch 3 in human fibroblasts
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and mammary epithelial cells delays the onset of senescence and extends cell lifespan [120, 121].
FGF and IGF pathways

FGFs are well-recognized for their critical roles in
embryonic development [122]. The mitogenic effect of
FGF has been demonstrated by promoting proliferation
while maintaining stemness of MSCs in vitro [123–125].
FGF2 treatment led to an early increase in telomere size
in MSCs, probably due to its ability to increase TERT
mRNA expression [126, 127]. FGF signals negatively regulated MSC senescence through interaction with PI3K/
AKT/MDM2 (mouse double minute-2 homolog) in the
mouse and through down-regulation of TGFβ expression in human MSCs [128, 129]. Surprisingly, FGF23 can
also induce premature senescence in human MSCs from
skeletal muscle via the p53/p21 oxidative-stress pathway
[130].
IGFs are considered detrimental to cell survival due
to their role in diminishing tissue resistance to oxidative
stress and shortening lifespan [131, 132]. In mouse, rat
and human primary vascular smooth muscle cells, IGFI
induces cellular senescence dependent on the upregulation of p53 [133]. Additional evidence has revealed that
IGF binding protein-5 is upregulated in the regulation of
premature senescence of umbilical vein endothelial cells
through a p53-controlled mechanism [134, 135]. These
findings may be due to the mechanism whereby IGFI is
capable of inducing telomere shortening [136]. However,
opposite results were found in human annulus fibrosus
cells as IGFI alleviates cellular senescence [137]. In this
scenario, the regulatory roles of both FGFs and IGFs
relating to cellular senescence are context-dependent.
HIF pathway

HIFs are composed of two different basic-helix-loophelix-PAS transcription factors, HIF1α and HIF1β [138].
It has been proposed that a classic cellular response to
hypoxia is cell cycle arrest at the G1/S interface through
the regulation of p27 expression in which HIF1α is a
major mediator [139, 140]. On the other hand, HIFs are
involved in the promotion of cancer growth and the loss
of HIFs induces the production of ROS and the activation of proteins p53 and p16 [141, 142]. HIF1α is involved
in the suppression of senescence through regulation of
p53 and p21 in human diploid fibroblasts [143]. When
expanded in hypoxic conditions, human MSCs and the
old human endothelial progenitor cells escape senescence
through regulation of HIF1α-TWIST-p21 axis [144, 145].
Moreover, hypoxia led to PI3K/AKT pathway activation
and elevated expression of Wnt coreceptor low-density
lipoprotein receptor-related protein 5 (LRP5), contributing to the promotion of self-renewal and decreased
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cellular senescence of marrow-isolated adult multilineage
inducible cells [146].

Immortalization of cells through genetic
modification
To achieve cell lifespan extension, biotechnological
methods are often used for direct manipulation of a cell’s
genome. However, concerns still exist regarding genomic
stability and tumorigenicity after genetic modification.
For MSCs and progenitor cells, the potential loss of differentiation ability after genetic modification is a problem that cannot be overlooked.
Genetic modification

The introduction of viral oncogenes/oncoproteins and
TERT are two typical methods for this type of genetic
modification (Table 1).

Viral oncogenes/oncoproteins

Viral oncogenes that are able to inactivate both pRb and
p53 can overcome M1 (a barrier in which normal cells
senesce and cease replication) and significantly prolong
cell lifespan. For several decades, simian virus 40 (SV40)
early region genes have been commonly used for cell
immortalization and cell line establishment [147, 148].
SV40 is limited to two proteins as the large T (LT) and
small t antigen (ST). LT is mainly responsible for the
SV40-extended lifespan based on its ability to interact
with growth suppressors—pRb and p53. LT binds to the
pRb-E2F complex via its pocket binding site including
AA101–118 and the J domain that acts as a chaperone,
leading to the dissociation of E2F from the LT-pRb complex [149]. Meanwhile, LT binds to p53 therefore suppressing the p53 pathway [150]. More interestingly, SV40
was reported to induce telomerase activity in primary

Table 1 Immortalization of primary cells for therapeutics and research
Immortalization

Cell type

References

Oncoprotein(s)

Human Articular chondrocytes, bone marrow endothelial cells, cranial suture
progenitors, foreskin keratinocytes, hepatocyte, keratinocytes, liver
renal proximal tubular epithelial cells, mammary epithelial cells,
marrow stromal cells, nucleus pulposus cells, podocyte cells, sinusoidal endothelial cells, umbilical cord blood endothelial progenitor
cells, umbilical vein endothelial cells, uterine cervix epithelial cells

[154, 233, 238, 287–303]

Animal Mouse articular chondrocytes, rat renal proximal tubular epithelial
cells

[304]

Human Prostate epithelial cells, neural precursors, embryonic stem cellderived MSCs

[160, 161, 305]
[162, 306]

Oncogene(s)
Oncoprotein(s) and oncogene(s)

Human Embryonic fibroblasts, keratinocytes

TERT

Human Adipose-derived stromal cells, amnion-derived stem cells, bone
[178, 215, 307–318]
marrow-derived MSCs, cementum-lining cells, cord blood MSCs,
dermal microvascular endothelial cells, embryonic stem cells, fetal
hepatocytes, hepatic stellate scavenger cells, neural progenitor cells,
osteoblasts, periodontal ligament progenitor cells, renal proximal
tubule epithelial cells, vocal fold fibroblasts
Animal Mouse temporomandibular joint disc cells

[319]

TERT and oncoprotein(s)

Human Adipose-derived stromal cells, amniotic fluid-derived mesenchymal
stem cells, bone marrow-derived MSCs, ovarian surface epithelial
cells, pancreatic β cells, pancreatic islet cells, periodontal ligament
fibroblasts, pulmonary microvascular endothelial cells, renal proximal tubule epithelial cells

[244, 247, 320–328]

Animal Rat ventricular cardiomyocytes

[329]

TERT and oncogene(s)

Human Fetal pancreatic epithelial cells, placenta-derived MSCs, adiposederived stromal cells

[246, 330–332]

Animal Bovine germ line stem cells

[163]

TERT, oncoprotein(s) and oncogene(s)

Human Bone marrow-derived MSCs

[333]

TERT and suppression of p53 or Rb pathway Human Mammary epithelial cells, ovarian surface epithelial cells

[176, 334, 335]

TERT and cyclin-dependent kinase 4

[336]

Human Bronchial epithelial cells

Mutant p53

Human Mammary epithelial cells

[337, 338]

Irradiation and oxidative stress

Human Mammary epithelial cells

[339, 340]

Chemical carcinogens
TERT and cytotoxic T lymphocyte-associated antigen 4-Ig

Human Mammary epithelial cells

[341]

Animal Syrian hamster dermal fibroblasts and embryo cells, rat hepatocytes

[342–344]

Human Bone marrow-derived MSCs

[345]
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human mesothelial cells, but not in primary fibroblasts
[151].
Human papillomavirus (HPV) is a small, doublestranded DNA virus that infects mucosal and cutaneous
epithelial tissue [152]. The high-risk strains including
HPV-8, -16, -18 and -31 cause malignant progression of
lesions, whereas the low-risk strains including HPV-6
and -11 cause benign warts and lesions [153]. The E6
and E7 proteins encoded by “high-risk” strains including
HPV-16 and -18 are oncoproteins that have been shown
to have transformation properties [154]. When used in
immortalization, E6 causes telomerase activation as well
as accelerating the degradation of p53 by the 26S proteasome, whereas E7 inactivates Rb by preventing the binding of pRb to the E2F transcription factor [155, 156].
Human T-lymphotropic virus type 1 (HTLV-1) is
the etiologic agent of adult T cell leukemia. Although
HTLV-2 is less pathogenic than HTLV-1, both of the
HTLV-1 and -2 Tax proteins, p40tax (Tax1) and p37tax
(Tax2), share the capacity to immortalize lymphocytes
in vitro [157]. HTLV-2 protein Tax2 demonstrates much
stronger efficacy than that of Tax1 in immortalizing
human T cells [158].
The myc oncogene family consists of several different
members including c-myc, N-myc, L-myc and B- myc.
c-myc expression is restricted to proliferating cells while
N-myc and L-myc expression is associated with cellular differentiation [159, 160]. Moreover, the oncogene
myc fulfils many of the expectations for a gene involved
in immortalization of primary cells alone [160, 161] or
cooperates with oncoproteins [162] or TERT [163].
B cell-specific Moloney murine leukemia virus integration site 1 (BMI1) which was identified as a c-myc-cooperating oncogene, is a critical transcriptional repressor
for maintenance of proper gene expression during development [164–166]. INK4a locus, which encodes p16 and
p19Arf, is an important target of BMI1 and overexpression of BMI1 extends replicative lifespan of human fibroblasts, probably through suppressing the p16-mediated
senescence pathway [167, 168].
TERT

Telomerase is composed of two core components: the
small nuclear ribonucleic acid (RNA) human telomerase
RNA, which serves as an internal template for the synthesis of telomeric repeats, and the protein TERT (or
hTERT in humans), which serves as a catalytic subunit
that synthesizes the new telomeric DNA from the RNA
template [22]. In most human primary cells, telomerase
is either absent or present at an insufficient level for telomere maintenance [169]. TERT is the determinant for
the presence of active telomerase [170, 171]. The introduction of ectopic expression of TERT is necessary for
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telomere-dependent senescence as it is able to significantly extend the lifespan of a variety of cell types, but
it alone is not sufficient to immortalize them [172–174].
Theoretically, the abrogation of the Rb and p53 pathways
with oncogenes or at a minimum, low p16 expression, is
indispensable for cell immortalization [175, 176]. However, there are still investigations showing that TERT
bypassed Rb and p53 pathway-dependent barriers to
immortalize cells alone [176–180].
Carcinogenic limitations and strategies

Despite the increasingly sophisticated strategies to
immortalize human cells, there is still some debate over
the risks upon integration of oncogenes into chromosomes. The primary safety concern with the use of a cell
line is the transmission of an oncogenic factor to the
host cells. Indeed, cells transduced with these oncogenes
underwent additional changes including full carcinogenesis-associated changes (Table 2). The persistent infection by a subset of HPVs, especially HPV-16 and HPV-18,
is etiologically linked to cervical cancer in women [181].
Deregulated overexpression of HPV E6 and E7 led to several alterations in cellular pathways and functions, which
is associated with malignant transformation of cells and
tumorigenesis [182]. In addition, HPV E6 oncoprotein
can interact with hTERT to promote carcinogenesis in
keratinocytes [183, 184].
SV40 or SV40 sequences were found in several types of
human cancers located in bone, brain, chest, etc. [185–
188]. Evidence has shown that SV40 can successfully
transform cell lines in vitro and induce tumors in neonatal hamsters in vivo [189–192]. The injection of SV40transformed cells into terminally ill human patients
caused subcutaneous tumor nodules [193]. Moreover,
SV40-transduced cells contained integrated SV40 DNA,
which was integrated at random positions on the cellular
chromosomes of host cells [194, 195], leading to the controversial question of whether the virus poses a threat for
further in vivo use.
Although introduction of hTERT is associated with
fewer phenotypic and karyotypic changes of cells compared with SV40, the tumorigenicity of hTERT-transfected human cells remains controversial as well [176].
Previous studies have claimed that the hTERT-transduced primary human fetal lung fibroblasts, ameloblastoma cells and bovine mammary epithelial cells showed
no malignant transformation [180, 196, 197]. Similarly,
the hTERT-immortalized human MSCs past 290 population doublings showed no sign of malignant transformation or tumorigenesis in vitro and in vivo as the cells
maintain contact inhibition and a stable protein expression profile as well as no tumor-like activity in immunedeficient mice [198–200]. Meanwhile, after subcutaneous
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Table 2 Malignant transformation and tumorigenesis during immortalization of primary cells
Immortalization

Cell type or animal

References

Oncoprotein(s)

Human Biliary epithelial cells, fetal keratinocytes, fibroblasts, keratinocytes,
mesothelial cells

[190, 346–349]

Animal Chinese hamster embryo fibroblasts, rabbit chondrocytes

[191, 350]

Oncoprotein(s) and oncogene(s)

Human Colon smooth muscle cells, embryonic esophageal epithelial cell,
epidermal keratinocytes, hepatocytes, primary fibroblasts, prostatic
epithelial cells, mammary epithelial cells

[351–358]

TERT

Human Astrocytes

[359]

TERT and viral oncoprotein(s)

Human Airway (bronchial) epithelial cells, endothelial cells, esophageal epithelial cells, fibroblasts, hematopoietic progenitor cells, mammary
epithelial cells, MSCs, ovarian surface epithelial cells

[202, 240, 360–368]

Animal Bovine adrenocortical cells

[369]

Human Mammary epithelial cells, MSCs

[370, 371]

TERT and oncogenes

Oncoprotein(s), oncogene(s) and growth factors Human Oral keratinocytes

[372]

Oncoprotein(s) and chemical carcinogens

Human Ectocervical and endocervical cells, oral keratinocytes

[373–377]

TERT, oncoprotein and alpha subunit of eukaryotic initiation factor 2

Human Kidney cells

[378]

injection with HPV-16 E6/E7 immortalized BMSCs into
Nonobese Diabetic/Severe Combined Immunodeficiency (NOD/SCID) mice for 3 days, no tumor mass was
observed compared to those injected with Hela cells in
which tumor mass was observable [201]. Even the introduction of TERT and SV40 or HPV-16 E6/E7 was sufficient to immortalize ovarian surface epithelial cells and
dermal papilla cells but not enough for tumor formation
[179, 202–205].
However, other groups argue about the increased
potential for tumor development in TERT-immortalized
cells. On monolayer cultures, human MSCs and fibroblasts avoid cell-to-cell contact inhibition, anchor to
culture dishes and tend to proliferate limitlessly [206,
207]. In clinical practice, elevated hTERT expression is
a diagnostic marker for tumor and the overexpression
of hTERT is claimed to be associated with an advanced
invasive stage of tumor progression and poor prognosis [208–210]. Moreover, there are still concerns about
genetic instability after TERT transfection or transduction. Spontaneous changes in c-myc proto-oncogene
expression and other genetic alterations have been
observed during in vitro culture of hTERT-immortalized
human cells [211, 212].
Despite safety concerns for the immortalized cells, there
are still some cases that successfully applied these cells for
in vivo organ and tissue restoration. For liver impairment,
Guo et al. [213] found that SV40-immortalized marmoset hepatic progenitor cells (MHPCs) injected into the
injured liver of fumarylacetoacetate hydrolase-deficient
mice repopulated with hepatocyte-like cells and MHPCs
were also implanted as cholangiocytes into bile ducts of
3.5-diethoxycarbonyl-1,4-dihydrocollodine-induced bile

ductular injured mice. Meanwhile, SV40-immortalized
human fetal liver cells differentiated into mature hepatocytes after being transplanted into liver injured mice
[214]. For brain damage, hTERT-immortalized cord
blood MSCs were injected into the traumatically injured
brain of a rat model and proliferated efficiently at the
injury site for 2 weeks and showed no tumor formation in
SCID mice after a 6-month observation [215].
To avoid persistent oncogene expression, conditional
immortalization technology was developed. Conditional
immortalization includes inserting a reagent mediate,
operator controllable gene to create a cell line that can
be expanded in a consistent fashion when the transgene
is active. When desired clinical quantities of cell material are achieved, the transgene can be deactivated by
the operator and the cells will return to a normal, postmitotic state. The conditional immortalization technology c-MycERTAM uses a combination of growth factor
and 4-hydroxytamoxifen (4-HT) to activate the c-MycER
transgene. In the absence of 4-HT, c-MycER is inactivated and the cells return to a normal phenotype [216].
Inactivation of SV40 LT was achieved using a temperature-sensitive mutant of the LT (SV40 tsA58) that is biologically active at permissive temperature (33.5 °C) but
inactive at a non-permissive temperature (39 °C) [217].
Different vectors can have influence on the expression
of transgenes. Unlike lentivirus, adenovirus does not
integrate transgenes into the host genome and thereby
can only provide a transient expression of the transgenes
[218]. However, this kind of expression time is not
controllable.
To acquire more accurate excision of oncogenes, sitespecific recombination systems were developed. Cre/
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LoxP technology involves engineering a transgene
flanked by LoxP sites. The transgene is activated until
Cre recombinase is added. However, the cre-lox system is not 100% efficient and cells that have not deleted
the transgene might require elimination [219, 220]. In
addition, a Tet on/off system uses tetracycline responsive elements (TRE) that consist of a Tet operator and
minimal promoter. The activation of the transgene and
the subsequent cell division is related to tetracycline or
doxycycline, which acts as a cue for activation (Tet-On)
or inactivation (Tet-Off ) [221, 222]. However, this technology still has the evident limitation termed “leakiness”,
where the transgene continues to express at a low level
even when the system is off [223]. Moreover, the transient activation of β-catenin was used to efficiently induce
hTERT activation while silencing β-catenin suppresses
the expression of hTERT [224]. Meanwhile, therapeutic
strategies concerning transient activation of telomerase
with small molecules, including the administration of 1%
N-acetylcarnosine lubricant eye drops for prevention and
treatment of cataracts, have been proven beneficial for
dogs and other animals [225]. Huang et al. have identified
that anthraquinone derivatives might be able to activate
hTERT expression without causing genetic alterations in
cells, whereas these cells fail to possess potent proliferative ability [226]. Interestingly, the introduction of some
adenovirus derived genes, including the early 4 region
(E4) of the adenoviral vector (AdE4), augments survival
of human endothelial cells [227, 228]. However, investigations into AdE4 gene products were largely overshadowed by the fact that these proteins not only orchestrated
many viral processes, but also overlapped with oncogenic
transformation of primary cells [229, 230]. Although
creation of conditionally immortalized cell lines has the
potential for therapeutic application, complete silence of
the transgene before introduction into the patient’s body
is still a concern that needs to be addressed.
Potential loss of differentiation capacity

Differentiation capacity of MSCs and progenitor cells
after immortalization is another concern that deserves
more attention. A variety of reports has claimed that
immortalization of progenitor cells will retain proliferative activity without compromising multipotent or
specific differentiation potential of primary cells from
species including human, mouse and porcine [231–237].
A similar phenomenon has been mentioned in human
MSCs immortalized with SV40 [238, 239]. After serial
transduction with hTERT, SV40 and H-Ras, human
MSCs still retain their multilineage differentiation potential even during tumorigenesis [240, 241]. Moreover,
Yang et al. [242] showed that hTERT-transduced human
BMSCs seeded on porous polylactic glycolic acid (PLGA)
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scaffold have better osteogenic differentiation ability than
primary human BMSCs seeded on scaffold. Similarly,
human BMSCs immortalized with hTERT and HPV16
E6/E7 displayed greater differentiation potential far
beyond the primary human BMSCs or even when human
BMSCs expressed HPV-16 E6/E7 alone [243]. Interestingly, Okamoto et al. [244] reported that human BMSCs
immortalized with hTERT and HPV-16 E6/E7 demonstrated significant clonal heterogeneity in differentiation
potential. A similar phenomenon was found in mouse
melanocyte progenitors that displayed distinct melanogenic differentiation potential [232]. More interestingly,
there were opposite results as human primary dental
pulp stem cells (DPSCs) are found to be approximately
60% more effective than hTERT-immortalized DPSCs
in osteogenic differentiation [245]. For human placentaderived MSCs immortalized with hTERT and BMI1, the
differentiation potential was lost [246]. This discrepancy may partially be due to different immortalization
strategies as the lost differentiation potential in ADSCs
due to “SV40+hTERT” introduction can be preserved
by “hTERT+BMI1” [247]. Moreover, cellular senescence counteracts the induction and reprogramming of
induced pluripotent stem cells and senescence related
INK4A/ARF and p53/p21 pathways are considered to be
involved in these processes [248–251].

Preconditioning of cells through matrix
microenvironment optimization
Although genetic manipulation is a popular strategy for
functional tissue engineering, it has limited clinical benefit due to its inherent risks [189, 193, 194]. For human
cells that are sensitive to external changes, matrix microenvironmental alterations may modify intercellular communication, leading to enhanced proliferation ability
without carcinogenic mutation [252, 253].
Cells in the body reside in a niche, a dynamic and complex environment, where extracellular cues provided
allow cells to survive and maintain their balance between
quiescence, self-renewal and differentiation [254, 255].
ECM, a versatile component that plays a key role in the
stem cell niche, interacts with the resident cells by modulating cell behavior through its physical, biochemical and
biomechanical properties [256, 257]. There is an increasing number of reports indicating that dECM is a promising substrate to maintain the stemness of expanded
cells by mimicking the in vivo niche [258, 259]. dECM
was found to improve the expansion capacity of human
BMSCs [260], human and porcine SDSCs [261, 262],
human umbilical cord MSCs [263] and porcine adipose
stem cells derived from the infrapatellar fat pad [264].
Interestingly, dECM deposited by SDSCs could also rejuvenate somatic cells such as porcine nucleus pulposus
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cells [265, 266] and replicatively senescent porcine chondrocytes [267]. These dECM-expanded cells were smaller
in size compared to those grown on plastic flasks. These
results are in accordance with the finding from Whitefield and coworkers in which, under time-lapse video
microscopy, the smaller cells were observed to continue
proliferation, while the larger cells became senescent and
exited the cell proliferation cycle [268].
Furthermore, current data indicate that dECM deposited by MSCs yields human adult SDSCs [269, 270] and
porcine adipose stem cells derived from the infrapatellar
fat pad [264] with better chondrogenic potential in vitro
and with better repair capacity for cartilage defects
in vivo [271]. Interestingly, BMSCs, a tissue-specific stem
cell for endochondral bone formation, could be greatly
recharged toward chondrogenic differentiation by expansion on dECM deposited by nonchondrogenic human
urine stem cells [272] or human BMSCs themselves [260].
More interestingly, a recent report showed that, despite
dECMs deposited by BMSCs and ADSCs enhancing the
proliferation ability of MSCs, they failed to yield expansion of cancer cells (HeLa, MCF7 and MDA-MB-231) in
terms of inhibiting the expansion ability of these cancer
cells [273]. This finding indicates that normal cell derived
dECM is not favorable for the growth of cancer cells.
Given the undesirable potential of carcinogenesis after
genetic modification from cell immortalization, dECM
tends to be a better alternative.
In addition to rescuing replicative and differentiation
capacities, dECM could reduce intracellular generation of
ROS in aged murine BMSCs [274] and in human BMSCs
[260] and umbilical cord MSCs [263]. Meanwhile, dECM
could enhance the anti-oxidative capacity of human
adult SDSCs [269] and protect umbilical cord MSCs
from oxidative stress-induced premature senescence
[275] to finally achieve better chondrogenic differentiation. Moreover, dECM could repress osteoclastogenesis
in bone marrow monocytes through the attenuation of
intracellular ROS [276]. All the above mentioned studies
confirmed the anti-senescence and anti-oxidative effect
of dECM as a culture substrate.
Mechanical cues, including stiffness and elasticity from
the surrounding matrix microenvironment, are important cellular inputs that sustain cell proliferation and
oppose cell senescence. Integrin-based focal adhesions
are the main adhesion complex dominating mechanosensing [277]. In our previous study, dECM-expanded
human BMSCs demonstrated increased expression of
integrin α2 and β5 [260], which are potentially involved
in the process of cell proliferation [278, 279]. As a powerful regulator of cell proliferation and survival, YAP/YAZ
act as mechanotransducer that is regulated by F-actin
cytoskeleton [280, 281]. Interestingly, dECM expansion
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was found to induce sustained activation of ERK1/2 as
well as phosphorylated cyclin D1 human BMSCs [260]
but decreased phosphorylated ERK in human adult
source SDSCs [261]. A similar phenomenon was found
in phosphorylated p38 expression in human SDSCs [261]
and human umbilical cord MSCs [263] after dECM preconditioning. These discrepancies might be explained
by the dual role of ERK [282] and p38 [283] signals that
play upon cell senescence. The expression of Wnt5a and
Wnt11a were also found to be upregulated following
dECM expansion [261].

Conclusions and perspective
Primary cells display a stable and long-term loss of proliferative capacity upon in vitro expansion despite continued viability and metabolic activity. This inability to
proliferate is due to progressive shortening of telomeres
during each replication which ultimately makes cells
reach their “Hayflick limit”, termed telomere-dependent
or replicative senescence. Meanwhile, there is another
kind of senescence referred to as premature senescence
since it can arrest cell growth long before reaching the
“Hayflick limit”. One type is stress-induced senescence
caused by the failure to simulate the in vivo supportive
environment, which puts pressure on cell proliferation
through the generation of ROS. In addition, both oncogenes and their counteracting tumor suppressors are
proven to provoke premature senescence. A variety of
signaling pathways are involved in all of these types of
senescence, in which the p53/p21 and p16/Rb pathways
are the two major signals involved. Oncogenes including
SV40 and HPV-16 E6/E7 inhibit the p53/p21 and p16/Rb
pathways, but are not able to immortalize primary cells
unless followed by the introduction of TERT, which elongates telomeres, thereby abrogating the effect of the end
replication problem. However, all of these genetic modification methods have the risk of virus introduction and
potential oncogenesis, which must be addressed before
its application into tissue engineering.
Optimization of the laboratory culture environment
[259], including modulation of oxygen level and cell density and the introduction of growth factors, and recently
discovered dECM preconditioning, is also an effective
strategy to fight against senescence. Despite the fact that
dECM deposited by MSCs from fetal [261] or young
donors [272] offers a better rejuvenation effect in promoting aged MSCs in both expansion and differentiation capacities compared to adult donors, the source of
these young cells was either allogenic or xenogeneic,
which might pose a potential risk of compromising the
donor [284] or immune rejection [285]. In this scenario,
cells donated by the patients themselves are considered
the best candidate. However, the elderly primarily suffer
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from degenerative disease and most of their autologous
cells may suffer from senescence, which was identified as
an influential factor in the quality of cells [286]. Given the
demand for a younger cell population and the situation
of carcinogenic transformation after genetic modification
for immortalization purposes, it raises the possibility of
combining genetic modification and environmental optimization strategies. In other words, we can immortalize
these senescent cells and utilize their deposited dECM
instead of the cells themselves to achieve a reduced
senescent status and enhanced proliferation potential
of expanded cells. The combination strategy might also
overcome the potential loss of differentiation capacity of
stem cells with the use of immortalization strategy alone.
Further investigation into this matrix microenvironmental preconditioning-based rejuvenation strategy may
offer important insights into possible means of providing
robust primary cells as therapeutic agents.
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